Pediatric Exclusivity Could Be Out-Licensed To Other Sponsors, FDA Suggests
This article was originally published in The Tan Sheet
Executive Summary
Congress should consider allowing pediatric exclusivity periods to be licensed to other sponsors as a mechanism for promoting pediatric study of drug products that do not have patent protection or exclusivity, FDA's pediatric exclusivity status report suggests.
You may also be interested in...
Pediatric Study Royalty Fund Would Be Created By Wellstone Amendment
Drug companies would be required to set aside a portion of product sales to fund pediatric research for off-patent drugs under an amendment Sen. Paul Wellstone (D-Minn.) will offer to the pediatric exclusivity reauthorization bill when it is considered on the Senate floor.
Pediatric Labeling Negotiations Limited To Six Months In Reauthorization Bill
Negotiations for pediatric labeling changes would be limited to six months under a proposed bill to reauthorize the pediatric exclusivity provisions.
Generic Famotidine Launch Delayed By Pepcid AC Pediatric Exclusivity
Private label famotidine 10 mg products will not launch until after April 15 due to FDA's Nov. 21 decision to grant J&J/Merck an additional six months of marketing exclusivity for Pepcid AC after reviewing pediatric data submitted by the firm.